Approval · Notice of Compliance 993 · 2000
SUPREFACT: Notice of Compliance 993
Issued June 12, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 993
- Date
- June 12, 2000
- Company
- Aventis Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Luteinizing hormone-releasing hormone (lh-rh) analogue
Products in this notice
Medicinal ingredients
- BUSERELIN ACETATE 1 MG per ML